



(51) International Patent Classification:

C07D 231/22 (2006.01) *A61K 31/515* (2006.01)
C07D 231/46 (2006.01) *A61K 31/357* (2006.01)
C07D 239/62 (2006.01) *A61K 31/366* (2006.01)
C07D 319/06 (2006.01) *A61P 9/00* (2006.01)
A61K 31/4155 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2012/060425

(22) International Filing Date:

16 October 2012 (16.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/548,036 17 October 2011 (17.10.2011) US

(71) Applicant: **JOHNS HOPKINS UNIVERSITY** [US/US];
100 North Charles Street, 5th Floor, Baltimore, Maryland
21201 (US).

(72) Inventor: **GUTHRIE, Daryl A.**; 3925 Beech Avenue,
Apartment 315, Baltimore, Maryland 21211 (US).

(74) Agents: **ADELSON, Lisa A.** et al.; Arnold & Porter LLP,
555 12th Street, NW, Washington, District of Columbia
20004-1206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: MELDRUM 'S ACID, BARBITURIC ACID AND PYRAZOLONE DERIVATIVES SUBSTITUTED WITH HYDROXYLAMINE AS HNO DONORS

(57) Abstract: The disclosed subject matter provides certain *N*-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or development of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.

